Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 18/20 | 1.00 |
| ▸ | MAOA | P21397 | 10/20 | 1.00 |
| ▸ | MAOB | P27338 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2755982 | 1.00 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL239764 | 1.00 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL236366 | 0.85 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL2755947 | 0.85 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL236367 | 0.85 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL17003410 | 0.84 | MAOA (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL17003411 | 0.84 | MAOA (1.00) | KDM1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL238860 | 0.83 | KDM1A (0.97) | KDM1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL238861 | 0.83 | KDM1A (0.97) | KDM1AMAOAMAOB | |
| SCHEMBL28160654 | 0.83 | MAOA (0.74) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616058-B2 | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use | ORYZON GENOMICS, S.A. (ES) | 2017-04-11 | — | — | US | claimed |
| US-20160045456-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2016-02-18 | — | — | US | claimed |
| US-8993808-B2 | Phenylcyclopropylamine derivatives and their medical use | ORYZON GENOMICS, S.A. (ES) | 2015-03-31 | — | — | US | claimed |
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS, S.A. (ES) | 2012-01-05 | — | — | US | claimed |
| EP-2389362-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | Oryzon Genomics, S.A. (ES) | 2011-11-30 | — | — | EP | claimed |
| US-20110252680-A1 | Surface mounted frame arrangement | ROSE DISPLAYS, LTD | 2011-10-20 | — | — | US | claimed |
| WO-2010084160-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2010-07-29 | — | — | WO | claimed |
| EP-3430015-B1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2025-08-06 | — | — | EP | disclosed |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | ORYZON GENOMICS S.A. (ES) | 2025-01-14 | — | — | US | disclosed |
| EP-3013424-B1 | LSD INHIBITORS FOR MODULATING CANCER STEM CELLS | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2024-09-25 | — | — | EP | disclosed |
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2022-12-08 | — | — | US | disclosed |
| WO-2021195723-A1 | \"METHODS FOR TREATMENT OF CORONAVIRUS INFECTIONS\ | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2021-10-07 | — | — | WO | disclosed |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-06-24 | — | — | US | disclosed |
| US-8993808-B2 | Phenylcyclopropylamine derivatives and their medical use | ORYZON GENOMICS, S.A. (ES) | 2015-03-31 | — | — | US | disclosed |
| US-20120108500-A1 | Compositions and Methods for Modulating Immunodeficiency Virus Transcription | THE J. DAVID GLADSTONE INSTITUTES | 2012-05-03 | — | — | US | disclosed |
| WO-2012047852-A2 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNODEFICIENCY VIRUS TRANSCRIPTION | THE J. DAVID GLADSTONE INSTITUTES (US) | 2012-04-12 | — | — | WO | disclosed |
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
| EP-2389362-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | Oryzon Genomics, S.A. (ES) | 2011-11-30 | — | — | EP | disclosed |
| US-20110252680-A1 | Surface mounted frame arrangement | ROSE DISPLAYS, LTD | 2011-10-20 | — | — | US | disclosed |
| WO-2010084160-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOA 4155/4885MAOB 3928/4885 |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | PDCD1, CD274, PDCD1LG2 | KDM1A 8/4885MAOA 54/4885MAOB 36/4885 |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOA 4155/4885MAOB 3928/4885 |
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | PNMT, ABCB1, SNCA | KDM1A 1515/4885MAOA 80/4885MAOB 143/4885 |
| US-20120108500-A1 | Compositions and Methods for Modulating Immunodeficiency Virus Transcription | KDM3B, DNMT3B, KDM1B | KDM1A 18/4885MAOA 1281/4885MAOB 1105/4885 |
| US-20160045456-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | PNMT, ABCB1, SNCA | KDM1A 1515/4885MAOA 80/4885MAOB 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.